Integra LifeSciences Holdings Corp.
Integra LifeSciences to Hold Second International Tissue Technologies Symposium on June 15 - 16, 2017 in Berlin, Germany
PLAINSBORO, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it is holding its second International Symposium on Tissue Technologies in Berlin, Germany on June 15 - 16, 2017.
Following the success of the first International Tissue Technologies Symposium in 2016, Integra is holding a second event, offering a two-day scientific symposium, which will bring together more than 100 surgeons from Europe and the United States. The 2017 International Symposium on Tissue Technologies will present an overview of different surgical techniques used in various medical fields, such as dermal reconstruction and regeneration, and plastic and reconstructive procedures in breast and complex abdominal wall repair. A faculty of world-renowned key opinion leaders will join the meeting to share their experience and viewpoints during the different scientific sessions and discussions.
"As a world leader in regenerative technologies, Integra is committed to offering a best-in-class medical education platform that will enable physicians to benefit from the experience of some of the world's leading plastic and reconstructive surgeons," said Stephane Corp, Integra's vice president, Tissue Technologies, Europe.
"We share with many surgeons a strong vision of all the scientific benefits brought by the soft tissue repair technologies. We believe that these technologies will continue to help improve patients' lives, and we are proud to offer a forum where practitioners can share best practices and techniques learned from their personal experience with patients."
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 2016. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Marie-Anne Girel (Europe)
+33 4 37 47 59 70
Laurene Isip (U.S.)
+ 609 750 7984
+ 1 609 750 2827
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Oxford Immunotec21.11.2017 15:16 | pressemeddelelse
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
Crown Bioscience Inc.21.11.2017 14:02 | pressemeddelelse
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
OmniComm Systems Inc.21.11.2017 14:02 | pressemeddelelse
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics
Nasdaq21.11.2017 11:32 | pressemeddelelse
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System
CloudCraze21.11.2017 08:02 | pressemeddelelse
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership
TESARO, Inc.20.11.2017 13:02 | pressemeddelelse
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum